Loading...
SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice
Persons with type 1 and type 2 diabetes have increased fracture risk, attributed to deficits in the microarchitecture and strength of diabetic bone, thought to be mediated, in part, by the consequences of chronic hyperglycemia. Therefore, to examine the effects of a glucose-lowering SGLT2 inhibitor...
Na minha lista:
| Udgivet i: | Bone |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4679447/ https://ncbi.nlm.nih.gov/pubmed/26211996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2015.07.025 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|